NIMG-59. EVALUATION OF THE RESPONSE ASSESSMENT CRITERIA IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Abstract BACKGROUND We sought to compare the Response Assessment in Neuro-Oncology (RANO), modified RANO (mRANO), and immunotherapy (iRANO) a large population of patients with newly diagnosed (nGBM) recurrent (rGBM) glioblastoma. METHODS Bidimensional measurements enhancing disease FLAIR sequence evaluation were performed by two independent readers on brain MRIs consecutive IDH-wildtype nGBM rGBM treated at single institution. Discrepancies evaluated third reader. Dates progression (PD) identified using RANO, mRANO, iRANO, other response assessment criteria variations. Spearman’s correlations between PFS OS calculated iterative multiple imputations for censored observations. RESULTS 526 580 cases included. not significantly different mRANO (0.69 [95% CI 0.62 0.75] vs. 0.67 [0.60, 0.73]) (0.48 [0.40, 0.55] 0.50 [0.42, 0.57]). Evaluation did improve correlation who received antiangiogenic therapy. Acquisition confirmation scans was associated increased only when PD within 12 weeks completion radiation nGBM. The use post-radiation MRI as baseline compared pre-radiation (0.67 0.73] 0.53 0.62]). iRANO similar among 98 175 immunotherapy. CONCLUSIONS demonstrated OS. can be omitted, while beneficial first after radiation. There trend favor scan add significant benefit